SIMCERE PHARMAC Return On Asset vs. Earnings Per Share
| S2P Stock | EUR 0.89 0.05 5.95% |
For SIMCERE PHARMAC profitability analysis, we use financial ratios and fundamental drivers that measure the ability of SIMCERE PHARMAC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well SIMCERE PHARMAC GRP utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between SIMCERE PHARMAC's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of SIMCERE PHARMAC GRP over time as well as its relative position and ranking within its peers.
SIMCERE |
SIMCERE PHARMAC GRP Earnings Per Share vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining SIMCERE PHARMAC's current stock value. Our valuation model uses many indicators to compare SIMCERE PHARMAC value to that of its competitors to determine the firm's financial worth. SIMCERE PHARMAC GRP is currently regarded as top stock in return on asset category among its peers. It also is currently regarded as top stock in earnings per share category among its peers creating about 1.45 of Earnings Per Share per Return On Asset. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SIMCERE PHARMAC's earnings, one of the primary drivers of an investment's value.SIMCERE Earnings Per Share vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
SIMCERE PHARMAC |
| = | 0.0344 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
SIMCERE PHARMAC |
| = | 0.05 X |
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
SIMCERE Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on SIMCERE PHARMAC. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of SIMCERE PHARMAC position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the SIMCERE PHARMAC's important profitability drivers and their relationship over time.
Use SIMCERE PHARMAC in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SIMCERE PHARMAC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SIMCERE PHARMAC will appreciate offsetting losses from the drop in the long position's value.SIMCERE PHARMAC Pair Trading
SIMCERE PHARMAC GRP Pair Trading Analysis
The ability to find closely correlated positions to SIMCERE PHARMAC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SIMCERE PHARMAC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SIMCERE PHARMAC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SIMCERE PHARMAC GRP to buy it.
The correlation of SIMCERE PHARMAC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SIMCERE PHARMAC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SIMCERE PHARMAC GRP moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SIMCERE PHARMAC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your SIMCERE PHARMAC position
In addition to having SIMCERE PHARMAC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Restaraunts Hotels Motels Thematic Idea Now
Restaraunts Hotels Motels
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Restaraunts Hotels Motels theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaraunts Hotels Motels Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in SIMCERE Stock
To fully project SIMCERE PHARMAC's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of SIMCERE PHARMAC GRP at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include SIMCERE PHARMAC's income statement, its balance sheet, and the statement of cash flows.